Drugs / BX-001N
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06097702 | Nov 2023 → Nov 2024 | ischemic disease | Bilix Co.,Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07164833 | Aug 2025 → Sep 2027 expected | acute kidney injury, ischemic disease | Bilix Co.,Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BX-001N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07164833 ↗ |
| Route | Intravenous | “after intravenous administration” NCT06097702 ↗ |